Side effects are the most common reason patients hesitate before starting a GLP-1 and the most common reason they stop early
From your seat in corporate credit, why does AI infrastructure matter so much, to investors right now
But follicles are remarkably resilient
The most frequent gastrointestinal side effects include: Nausea and vomiting : Very common, typically most pronounced during dose escalation Diarrhoea : Common to very common, though usually mild to moderate Constipation : Can occur due to delayed gastric emptying and reduced gut motility Abdominal pain and discomfort : Common Dyspepsia and gastro-oesophageal reflux : May worsen in susceptible individuals Other important adverse effects include: Gallbladder disorders : Cholelithiasis and cholecystitis have been reported, particularly with weight loss Dehydration and acute kidney injury : May occur secondary to severe gastrointestinal symptoms Hypoglycaemia : Risk increases when used with insulin or sulfonylureas, which may require dose adjustment Current limited evidence does not suggest an increased risk of inflammatory bowel disease (IBD) flares with GLP-1 agonists, though more data are needed
We hypothesized that a secreted protein between cells contributes to the loss of neurons in PD by affecting the sensitivity of dopaminergic neurons to ferroptosis
Related Stories Rising antimicrobial resistance in children threatens life-saving antibiotic effectiveness Gut microbial metabolites may shape vulnerability to stress-related mental disorders Study: Why First Nations children still face health care inequalities The researchers analyzed data obtained from only those individuals the LHS insured for two or more years before the data extraction date
